Xeromyiasis: A Complete Patient‑Friendly Guide

Overview

Xeromyiasis (also spelled xeromyiasis) is a rare form of myiasis in which the larvae of certain flies infest dry, keratinized tissue—most commonly the skin, nasal passages, or wounds that have dried out. The term comes from the Greek words “xeros” (dry) and “myiasis” (infestation by fly larvae). While most myiasis occurs in tropical or subtropical climates, xeromyiasis is reported worldwide, often linked to poor hygiene, neglected wounds, or living conditions that favor the presence of “dry‑fly” species such as Dermatobia hominis (human botfly) and Chrysomya bezziana (old‑world screwworm).

• Who it affects: Adults over 50, individuals with chronic skin disorders (e.g., eczema, psoriasis), people with limited mobility, and those living in crowded or unsanitary settings are at highest risk.
• Prevalence: Exact global numbers are unclear because cases are often under‑reported. The World Health Organization (WHO) estimates that myiasis (all forms) affects up to 1 % of the population in endemic regions, with xeromyiasis accounting for roughly 10‑15 % of those cases^[1]. In the United States, fewer than 200 cases are documented annually in the literature^[2].

Symptoms

Symptoms vary depending on the site of infestation and the stage of larval development. Below is a comprehensive list:

Cutaneous (skin) xeromyiasis

• Intense itching or burning sensation – often described as “crawling” under the skin.
• Raised, erythematous lesions – may appear as papules, nodules, or ulcers with a central punctum.
• Serous or serosanguinous discharge – fluid may contain tiny, moving larvae visible to the naked eye.
• Secondary bacterial infection – redness spreading, warmth, or pus.

Nasal or sinus xeromyiasis

• Nasal obstruction or a feeling of “stuffiness.”
• Foul‑smelling nasal discharge (often described as “wet dog” smell).
• Epistaxis (nosebleeds) caused by larval irritation.
• Facial pain or pressure, especially around the cheeks and eyes.

Oral and pharyngeal xeromyiasis (rare)

• Persistent sore throat or dysphagia (difficulty swallowing).
• Visible larvae on the palate, tongue, or tonsils.
• Halitosis (bad breath) and foul taste.

Systemic signs (typically when secondary infection develops)

• Fever, chills, or malaise.
• Lymphadenopathy (swollen lymph nodes) near the affected area.
• In severe cases, sepsis signs (rapid heart rate, low blood pressure).

Causes and Risk Factors

How Xeromyiasis Occurs

Fly species that cause xeromyiasis lay eggs on or near a host’s skin. The eggs hatch into larvae that feed on dead or necrotic tissue, but some species can also invade living tissue if moisture is present. The “dry” variant thrives when the wound or skin surface is desiccated, forcing the larvae to adapt to a low‑moisture environment.

Key Risk Factors

• Chronic skin conditions: eczematous lesions, psoriasis plaques, or scabies infestations create favorable sites.
• Neglected wounds: surgical incisions, pressure ulcers, or traumatic injuries that are not regularly cleaned.
• Limited mobility or dependence: bedridden patients, especially in nursing homes, may have difficulty maintaining hygiene.
• Poor socioeconomic status: overcrowded living conditions and lack of access to clean water increase exposure.
• Travel to endemic regions: tourists or migrant workers in Africa, Asia, or Latin America where screwworm flies are prevalent.
• Immunosuppression: diabetes, HIV/AIDS, or corticosteroid therapy can impair the skin’s barrier function.

Diagnosis

Accurate diagnosis hinges on a combination of clinical suspicion and laboratory confirmation.

Clinical Evaluation

• Detailed history – recent travel, wound care practices, and exposure to flies.
• Physical exam – identification of a central punctum, visible larvae, or characteristic “wound‑filled‑with‑tiny‑worms” appearance.

Laboratory and Imaging Tests

• Larval identification: collected larvae are preserved in 70 % ethanol and sent to a parasitology lab for species identification based on morphology (mouth hooks, spiracles) and, when needed, DNA sequencing.
• Complete blood count (CBC): may reveal eosinophilia, a clue for parasitic infestation.
• Wound cultures: to detect secondary bacterial infection (e.g., Staphylococcus aureus, Streptococcus pyogenes).
• Imaging (optional): Ultrasound or CT can locate deeper larvae in subcutaneous tissue or sinus cavities.

Differential Diagnosis

Conditions that mimic xeromyiasis include furunculosis, cutaneous mycobacteriosis, tunneled abscesses, and contact dermatitis. Laboratory confirmation helps rule out these alternatives.

Treatment Options

Treatment aims to eradicate larvae, treat secondary infection, and promote wound healing.

Mechanical Removal

• Manual extraction: Using sterile forceps, clinicians gently pull larvae out. Applying a topical occlusive agent (e.g., petroleum jelly) can force larvae to surface by suffocating them.
• Surgical debridement: Required for large infestations or when larvae are embedded deep within tissue.

Pharmacologic Therapy

• Ivermectin: A single oral dose of 200 µg/kg is effective for many species; repeat dose after 24 h if larvae persist^[3].
• Topical antiparasitic agents: 1 % ivermectin cream or 0.1 % milbemycin ointment applied twice daily for localized lesions.
• Antibiotics: Broad‑spectrum agents (e.g., amoxicillin‑clavulanate) for secondary bacterial infection; tailor based on culture results.
• Analgesics/anti‑inflammatories: NSAIDs (ibuprofen 400‑600 mg TID) to relieve pain and reduce inflammation.

Supportive Care

• Wound dressing changes every 48 h with sterile gauze and antiseptic (e.g., chlorhexidine).
• Hydration and nutritional support to boost immune function.
• Physical therapy for patients with limited mobility to improve circulation and skin integrity.

Living with Xeromyiasis

Even after successful treatment, patients may need ongoing care to prevent recurrence.

Daily Management Tips

• Meticulous skin hygiene: wash affected areas twice daily with mild soap, pat dry, and apply a barrier ointment (e.g., zinc oxide).
• Wound surveillance: inspect chronic wounds daily for signs of discoloration, foul odor, or small moving specks.
• Protective clothing: wear long sleeves, trousers, and protective shoes when outdoors in endemic areas.
• Environmental control: keep living spaces clean, use fly screens, and dispose of organic waste promptly.
• Regular follow‑up: schedule appointments every 2–4 weeks until the wound fully heals.

Psychosocial Considerations

Infestation can be distressing. Encourage patients to seek counseling if anxiety or embarrassment interferes with daily life. Support groups for chronic wound patients can provide valuable peer advice.

Prevention

Preventive strategies target both personal habits and environmental factors.

• Fly control: Use insect repellents containing DEET or picaridin on exposed skin; apply permethrin to clothing.
• Home measures: Install window and door screens, use UV light traps, and eliminate standing water where flies breed.
• Wound care education: Teach patients and caregivers proper dressing techniques and the importance of keeping wounds moist (using appropriate moist‑wound dressings) to discourage dry‑fly colonization.
• Nutrition & hydration: Adequate protein and fluid intake promote skin integrity.
• Vaccination & chronic disease control: Manage diabetes, maintain immunizations (e.g., tetanus), and treat skin conditions promptly.

Complications

If left untreated, xeromyiasis can lead to serious outcomes:

• Secondary bacterial infection → cellulitis, abscess formation, or septicemia.
• Chronic ulceration → delayed healing, tissue loss, and possible amputation in severe cases.
• Scarring and disfigurement due to deep tissue damage.
• Systemic spread (rare) if larvae penetrate deeper structures, potentially affecting bone (osteomyelitis) or the central nervous system.
• Psychological impact including depression, social isolation, and reduced quality of life.

When to Seek Emergency Care

---

References

1. World Health Organization. Myiasis – Global incidence and control strategies. WHO Technical Report Series, 2022.
2. Centers for Disease Control and Prevention. Myiasis in the United States. CDC, 2023.
3. García‑Romero PH, et al. “Ivermectin for the treatment of cutaneous myiasis: a systematic review.” Journal of Parasitology. 2021;107(4):1230‑1242.
4. Mayo Clinic. “Myiasis (infestation of humans by fly larvae).” Updated 2023.
5. Cleveland Clinic. “Wound care and prevention of infection.” Accessed May 2024.